Abstract

Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group 1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positive ERCC1 expression. The objective of this study was to evaluate whether ERCC1 expression is associated with response to platinum-based chemotherapy in ovarian cancers. MEDLINE, PubMed, Web of Science and CNKI databases were used for searching studies relating to ERCC1 protein expression and response to platinum-based chemotherapy in ovarian cancers. Statistical analysis was based on the method for a fixed effects meta-analysis. Pooled odds ratios (ORs) with 95% confidence intervals for ERCC1 protein expression and response to platinum- based chemotherapy were generated. Publication bias was investigated with Begg's test. Five studies involving 306 patients with ovarian cancer were included. Compared to patients with positive ERCC1 expression, those with negative ERCC1 expression had a better response to platinum-based chemotherapy. The pooled OR was 5.264 (95% CI: 2.928 - 9.464, P < 0.001) and publication bias was not found (P = 0.904). The result was similar in both in Asians and Caucasians (P < 0.001 and P = 0.028, respectively). ERCC1 protein expression status is significantly associated with response to platinum-based chemotherapy in ovarian cancers.

Highlights

  • Ovarian cancer is the major cause of death among the gynecological malignancies (Siegel et al, 2012)

  • In the current meta-analysis, we evaluated the association between ERCC1 expression and response to platinum-based chemotherapy in patients with ovarian cancer

  • The results indicated that the patients with negative ERCC1 expression had a better response to platinum-based chemotherapy than those with positive ERCC1 expression

Read more

Summary

Introduction

Ovarian cancer is the major cause of death among the gynecological malignancies (Siegel et al, 2012). The nucleotide excision repair (NER) system plays a key role in mediating resistance or sensitivity to platinum chemotherapeutic agents (Rabik & Dolan, 2007). It repairs platinum-induced DNA damage by altering the helical structure of the DNA molecule and interfering with DNA replication and transcription. Recent studies indicated ERCC1 protein expression could be predictive of sensitivity to platinum-based chemotherapy in ovarian cancers. These studies were of small sample size and have shown inconsistent results. We performed a meta-analysis of the published literature to assess an association between ERCC1 protein expression and response to platinumbased chemotherapy in patients with ovarian cancer

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call